Observational Study of Lamotrigine
1 other identifier
observational
60
1 country
1
Brief Summary
The purpose of this study is to assess efficacy, safety and tolerability of lamotrigine as used in a natural clinical setting, to examine the positive effects of lamotrigine, and the reasons why some patients choose to continue or discontinue lamotrigine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2001
CompletedFirst Submitted
Initial submission to the registry
March 3, 2006
CompletedFirst Posted
Study publicly available on registry
March 7, 2006
CompletedMarch 23, 2007
March 1, 2007
March 3, 2006
March 22, 2007
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Patients who are about to be prescribed lamotrigine as an appropriate treatment for their epileptic disorder
You may not qualify if:
- Patients with mental retardation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Northwell Healthlead
- GlaxoSmithKlinecollaborator
Study Sites (1)
Long Island Jewish Medical Center
New Hyde Park, New York, 11040, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alan Ettinger, MD
Northwell Health
Study Design
- Study Type
- observational
- Observational Model
- DEFINED POPULATION
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
March 3, 2006
First Posted
March 7, 2006
Study Start
October 1, 2001
Last Updated
March 23, 2007
Record last verified: 2007-03